Docoh
Loading...

PULM Pulmatrix

News

From Benzinga Pro
Pulmatrix Granted U.S. Patent Titled 'Monovalent metal cation dry powders for inhalation'
16 Nov 21
News, Legal
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6272&f=G&l=50&d=PTXT&p=126&S1=20211116&OS=20211116&RS=20211116
12 Health Care Stocks Moving In Monday's Pre-Market Session
15 Nov 21
Pre-Market Outlook, Markets, Movers
Pulmatrix Q3 EPS $(0.15) Up From $(0.31) YoY, Sales $1.07M Down From $4.37M YoY
10 Nov 21
Earnings, News
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.15) per share. This is a 51.61 percent increase over losses of $(0.31) per share from the same period last year. The company reported $1.07 million in sales this
Pulmatrix Announces Resolution Of Contract Dispute With Cipla; Cipla Will Continue To Reimburse Pulmatrix For 50% Of Third Party Costs For Development Of Pulmazole
9 Nov 21
News, Legal
Pulmatrix, Inc. (NASDAQ:PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today
12 Health Care Stocks Moving In Friday's Intraday Session
29 Oct 21
Intraday Update, Markets, Movers
12 Health Care Stocks Moving In Friday's Pre-Market Session
29 Oct 21
Pre-Market Outlook, Markets, Movers
12 Health Care Stocks Moving In Thursday's After-Market Session
28 Oct 21
Movers
Gainers
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
12 Oct 21
Biotech, Earnings, News, Penny Stocks, Offerings, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11)
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
8 Oct 21
Biotech, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, IPOs, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7)
Looking Into Pulmatrix's Return On Capital Employed
22 Sep 21
Earnings
According to Benzinga Pro data, during Q2, Pulmatrix (NASDAQ:PULM) posted sales of $2.25 million. Earnings were up 5.78%, but Pulmatrix still reported an overall loss of $3.85 million.